MEA Kidney Cancer Diagnostics And Therapeutics Market

MEA Kidney Cancer Diagnostics and Therapeutics Market Size (2023 to 2028)

The Middle East and Africa Kidney Cancer Diagnostics and Therapeutics Market was worth USD 0.19 billion in 2023 and estimated to be growing at a CAGR of 5.15%, to reach USD 0.24 billion by 2028.

The rising number of kidney cancer deaths weighs heavily on regional government as people demand accurate diagnosis and treatment for this critical disease. Some of the factors influencing the growth of the MEA kidney cancer diagnosis and therapeutics market include increased presence of carcinogens in common consumables, high exposure to toxic substances in factories and industrial environments, lack of knowledge about causative agents, symptoms, and preventive measures against kidney cancer, increased health care costs and deterred end-stage kidney cancer patients from seeking an optimal diagnosis.

With the increasing incidence of kidney cancer, there is a high demand for accessible and affordable diagnostic and treatment procedures. According to the GLOBOCAN statistics, over 175,000 people died from kidney cancer and its complications in 2018. These numbers represent nearly 1.82% of total cancer deaths across the globe. As kidney cancer research organizations and companies struggle to develop effective drugs due to tight budgets, governments and international authorities offer funds and grants to support the market.

Several international companies are looking into regional expansion and new products in unmet market regions. All these activities drive the overall growth of the MEA kidney cancer diagnostics and therapeutics market.

Kidney cancer patients are often faced with delayed diagnosis due to the unstable nature of this type of cancer. Many patients with kidney cancer are diagnosed at the end stage, which reduces the options for various treatments. This can be a limiting factor for the growth of the MEA kidney cancer diagnosis and treatment market. Other factors such as the low success rate of cancer medication, lack of funds for clinical trials, and stringent regulatory issues for approvals will cause the market to slow down in the years to come. The burden of monitoring kidney cancer incidence shifts to hospitals and medical research organizations as they strive to develop new diagnostic and therapeutic procedures. This calls into question the market's growth rate, especially in remote areas of the MEA region.

This research report on the MEA kidney cancer diagnostics and therapeutics market has been segmented and sub-segmented into the following categories:

By Type:

• Transitional Cell Cancer
• Renal Cell Carcinoma
• Renal Sarcoma
• Others

By Tests:

• Biopsy
• CT Scan
• Cystoscopy
• Intravenous Pyelogram
• Kidney Ultrasound

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

In 2022, Saudi Arabia had the largest market share and was expected to offer significant growth opportunities in the MEA kidney cancer diagnostics and therapeutics market in the years to come. Various factors such as solid healthcare infrastructure, growing patient awareness, high presence of kidney disorders, increased availability of resources, cheap labor, and rapid manufacturing regulations will drive the market growth in this region. In Saudi Arabia, kidney cancer accounts for approximately 3.65% of all cancers in men and 2.22% in women. In the early 2000s, nearly 139 cases of kidney cancer were recorded, 55.32% in men and 44.61% in women. The incidence rate was recorded at 1.6 per 100,000 for men and 1.3 per 100,000 for women.

Other regions such as the United Arab Emirates, Egypt, South Africa, Qatar, and Turkey will grow steadily due to improving healthcare facilities, supportive reimbursement policies, early availability, and adoption of the latest diagnostics and therapeutics devices for kidney cancer.

KEY MARKET PLAYERS:

Companies playing an influential role in the MEA kidney cancer diagnostics and therapeutics market profiled in this report are GlaxoSmithKline, Bayer, Pfizer, Sanofi S.A, Hoffmann La Roche, Novartis, and Abbott Laboratories.